170 related articles for article (PubMed ID: 28434898)
1. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes.
Zhang Q; Zhang W; Li Z; Bai C; Li D; Zheng S; Zhang P; Zhang S
Diagn Microbiol Infect Dis; 2017 Jul; 88(3):247-251. PubMed ID: 28434898
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections caused by Escherichia coli producing AmpC β-lactamases: epidemiology and clinical features.
Pascual V; Alonso N; Simó M; Ortiz G; Garcia MC; Xercavins M; Rivera A; Morera MA; Miró E; Espejo E; Navarro F; Gurguí M; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1997-2003. PubMed ID: 27549108
[TBL] [Abstract][Full Text] [Related]
4. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S
Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.
Denis B; Lafaurie M; Donay JL; Fontaine JP; Oksenhendler E; Raffoux E; Hennequin C; Allez M; Socie G; Maziers N; Porcher R; Molina JM
Int J Infect Dis; 2015 Oct; 39():1-6. PubMed ID: 26189774
[TBL] [Abstract][Full Text] [Related]
7. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
10. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
12. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.
Navarro-San Francisco C; Mora-Rillo M; Romero-Gómez MP; Moreno-Ramos F; Rico-Nieto A; Ruiz-Carrascoso G; Gómez-Gil R; Arribas-López JR; Mingorance J; Paño-Pardo JR
Clin Microbiol Infect; 2013 Feb; 19(2):E72-9. PubMed ID: 23231088
[TBL] [Abstract][Full Text] [Related]
13. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and risk factors for infections due to AmpC β-lactamase-producing Escherichia coli.
Pascual V; Ortiz G; Simó M; Alonso N; Garcia MC; Xercavins M; Rivera A; Morera MA; Miró E; Espejo E; Navarro F; Gurguí M; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
J Antimicrob Chemother; 2015 Mar; 70(3):899-904. PubMed ID: 25468902
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
17. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
[TBL] [Abstract][Full Text] [Related]
19. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
